Sunesis Pharmaceuticals has extended the timeline for its vecabrutinib dose-escalation study, which is evaluating the drug for adults with chronic lymphocytic leukemia and other B cell cancers. Sunesis will also increase the number of patients in the 50-mg group to six after one participant experienced adverse events and another patient's disease progressed, with results from the Phase Ib study expected to be ready this fall, according to interim CEO Dayton Misfeldt.
Sunesis extends dose-escalation study timeline for vecabrutinib
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.